Wolfe Research analyst Andy Chen downgraded Intellia Therapeutics (NTLA) to Peer Perform from Outperform.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTLA:
- FDA appoints Richard Pazdur as Director of CDER
- Intellia Therapeutics downgraded to Hold from Buy at JonesResearch
- Intellia Therapeutics downgraded to In Line from Outperform at Evercore ISI
- Intellia Reports Favorable Phase 1 Data for Nex-Z
- Intellia announces ‘positive’ follow-up data from ongoing Phase 1 nex-z trial